博濟醫藥(300404.SZ)半年度預盈1150萬元–1296萬元
格隆匯 8 月 18日丨博濟醫藥(300404.SZ)公佈,預計2020年半年度歸屬於上市公司股東的淨利潤1150萬元–1296萬元,同比上升290.49%–340.07%。業績變動原因如下:
1、報告期內,受新冠肺炎疫情的影響,公司及行業上下游推遲復工,在研項目進度緩慢,公司一季度營業收入及淨利潤均有所下降。二季度,隨着公司及上下游復產復工,公司的業務訂單承接逐步恢復正常,公司在研項目進度逐步恢復;
2、報告期內,公司新增合同金額約2.31億元,較上年同期增長12.93%。主營業務收入較上年同期增加,毛利也有所上升;
3、報告期內,預計非經常性損益對歸屬於上市公司股東的淨利潤影響約為200萬元—500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.